Table 2.
Early AMD*
|
Late AMD**
|
|||
---|---|---|---|---|
No. at Risk | % (N) | No. at Risk | % (N) | |
|
||||
Overall | 3685 | 4.1% (129) | 3802 | 2.3% (34)† |
White | 1486 | 5.3% (72) | 1549 | 4.1% (23) |
Black | 938 | 1.6% (15) | 949 | 0.4% (1) |
Hispanic | 808 | 3.3% (24) | 841 | 0.8% (4) |
Chinese | 453 | 4.5% (18) | 463 | 2.2% (6) |
Men | 1727 | 3.7% (56) | 1783 | 2.8% (18) |
White | 706 | 3.7% (27) | 737 | 1.6% (12) |
Black | 417 | 1.6% (6) | 420 | 1.1% (1) |
Hispanic | 379 | 3.9% (13) | 395 | 0.2% (1) |
Chinese | 225 | 4.7% (10) | 231 | 3.7% (4) |
Women | 1958 | 4.3% (73) | 2019 | 2.1% (16) |
White | 780 | 6.4% (45) | 812 | 4.0% (11) |
Black | 521 | 1.6% (9) | 529 | 0.0% (0) |
Hispanic | 429 | 2.6% (11) | 446 | 1.1% (3) |
Chinese | 228 | 4.3% (8) | 232 | 1.1% (2) |
Incidence estimates overall (all participants and by race/ethnicity) were age- and sex-standardized to the 2010 U.S. Census population; incidence estimates stratified by sex (all men or women and by race/ethnicity) were age-standardized to the 2010 U.S. Census population.
Early AMD was defined as no AMD at baseline examination (visit 2) but the presence of early AMD at follow-up examination (visit 5).
Late AMD was defined as either no AMD or early AMD at baseline examination (visit 2) but the presence of late AMD at follow-up examination (visit 5).
Among participants with late AMD at follow-up examination (visit 5) (n=34), five participants exhibited no AMD and 29 participants presented with early AMD at baseline examination (visit 2).